Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Onpattro (patisiran) for the Treatment of Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

Onpattro™ (patisiran) is indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis. Photo: Business Wire



  • Onpattro
  • Onpattro
  • Onpattro

Go Top